Avantor, Inc.
AVTR Healthcare Medical Instruments & Supplies
Avantor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 billion, down 3.41% from fiscal 2024.
- Revenue
- +4.59%
- EPS
- +128.9%
- Free cash flow
- −9.03%
- Total debt
- −4.51%
Quarter to September 2026, against a year earlier
Follow AVTR
Alert me
Avantor, Inc. (AVTR) P/E ratio
As of 5 November 2026, Avantor, Inc. (AVTR) trades at a P/E ratio of 30.3×. Over the past ten years it has ranged from 0.0× (September 2026) to 341× (January 2021); the current reading is higher than 50% of that period. That is in line with the Medical Instruments & Supplies industry median of 30.3× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 20.1× | (57.66%) |
| FY2023 | 47.4× | 130.60% |
| FY2022 | 20.6× | (58.05%) |
| FY2021 | 49.0× | (84.33%) |
| FY2020 | 313× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 30.1× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 29 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RGEN Repligen Corporation compare | n/m |
| BAX Baxter International Inc. compare | n/m |
| BLCO Bausch + Lomb Corporation compare | n/m |
| TFX Teleflex Incorporated compare | n/m |
| COO The Cooper Companies, Inc. compare | 21.7× |
| ALGN Align Technology, Inc. compare | 23.1× |
| AVTR Avantor, Inc. | 30.3× |
| ATR AptarGroup, Inc. compare | 34.6× |
| SOLV Solventum Corporation compare | 97.3× |
| Medical Instruments & Supplies industry median | 30.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on AVTR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement